MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Retained Earnings 2011-2026 | ZYNE
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -275 M | -239 M | -202 M | -151 M | -118 M | -78 M | -46 M | -22.6 M | -10 M | -4.36 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.36 M | -275 M | -115 M |
Quarterly Retained Earnings Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -295 M | -285 M | -275 M | -267 M | -258 M | -248 M | -239 M | -231 M | -220 M | -210 M | -202 M | -202 M | -202 M | -202 M | -151 M | -151 M | -151 M | -151 M | -118 M | -118 M | -118 M | -118 M | -78 M | -78 M | -78 M | -78 M | -46 M | -46 M | -46 M | -46 M | -22.6 M | -22.6 M | -22.6 M | -22.6 M | -10 M | -10 M | -10 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10 M | -295 M | -136 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.14 | -1.73 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
1.06 B | $ 2.63 | - | $ 1.38 B | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.19 | -1.64 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.39 | 1.98 % | $ 634 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.56 | 0.07 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 6.67 | -0.07 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 49.34 | -1.36 % | $ 1.61 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.22 | -8.65 % | $ 21.3 M |  China |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.69 | -0.88 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 5.14 | -0.77 % | $ 677 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.96 | -0.43 % | $ 2.54 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.54 | -2.13 % | $ 4.39 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.96 | -0.13 % | $ 55.7 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.81 | -0.96 % | $ 18.9 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.04 | -0.12 % | $ 1.2 B | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.64 | -0.61 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-295 M | $ 2.13 | -1.84 % | $ 287 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 13.91 | -0.22 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.44 | -2.36 % | $ 6.97 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.37 | 0.37 % | $ 5.91 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.79 | 5.63 % | $ 144 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 9.08 | -1.3 % | $ 645 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.76 | 0.96 % | $ 235 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.63 | 3.22 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 8.97 | -0.54 % | $ 5.54 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.63 | -0.61 % | $ 17 M | USA |